About Medicine OnLine Medicine OnLine Home PageCancer LibrariesDoseCalc OnlineOncology News
Cancer ForumsMedline SearchCancer LinksGlossary






spacer
DoseCalc OnLine
spacer Guide To Oncology Regimens


DISEASE: Lymphoma: Non Hodgkin's

Select a REGIMEN:

CHOP
CHOP-BLEO
COMLA
COP
CVP-1
DHAP
ESAP
MACOP-B
MIV
m-BACOD
PROMACE-CYTABOM
VACOP-B



DISEASE: Lymphoma: Non Hodgkin's

REGIMEN: CHOP

    CYCLOPHOSPHAMIDE [CTX] 750 mg/m2 IV... D1

    DOXORUBICIN [DOX] 50 mg/m2 IV... D1
    Caution: Monitor cumulative dose (cardiac toxicity)

    VINCRISTINE [VCR] 1.4 mg/m2 IV... D1
    Maximum dose is 2 mg

    PREDNISONE [Pred] 100 mg per day PO... D1-5

CYCLE: 21 days
REFER: Skeel RT: Handbook of Cancer Chemotherapy, 3rd Ed. Little, Brown & Co. 1991; 343.




DISEASE: Lymphoma: Non Hodgkin's

REGIMEN: CHOP-BLEO

    CYCLOPHOSPHAMIDE [CTX] 750 mg/m2 IV... D1

    DOXORUBICIN [DOX] 50 mg/m2 IV... D1
    Caution: Monitor cumulative dose (cardiac toxicity)

    VINCRISTINE [VCR] 2 mg IV... D1,5
    Maximum dose is 2 mg

    PREDNISONE [Pred] 100 mg per day PO... D1-5

    BLEOMYCIN [BLEO] 15 units per day IV... D1-5
    Caution: Monitor cumulative dose (pulmonary toxicity)

CYCLE: 14 or 21 days
REFER: Rodriguez V, et al: BLOOD 1977; 49:325-333.




DISEASE: Lymphoma: Non Hodgkin's

REGIMEN: COMLA

    CYCLOPHOSPHAMIDE [CTX] 1500 mg/m2 IV... D1

    VINCRISTINE [VCR] 1.4 mg/m2 IV... D1,8,15
    Maximum dose is 2 mg

    METHOTREXATE [MTX] 120 mg/m2 IV... D22,29,36,43,50,57,64,71

    LEUCOVORIN [Leu] 25 mg/m2 PO... D23,30,37,44,51,58,65,72
    q6h x 4 doses beginning 24 hr post MTX

    CYTARABINE [ARA-C] 300 mg/m2 IV... D22,29,36,43,50,57,64,71

CYCLE: 91 days
REFER: Gaynor ER, et al: J CLIN ONCOL 1985; 3:1596-1604.




DISEASE: Lymphoma: Non Hodgkin's

REGIMEN: COP

    CYCLOPHOSPHAMIDE [CTX] 400 - 800 mg/m2 IV... D1

    VINCRISTINE [VCR] 2 mg IV... D1
    Maximum dose is 2 mg

    PREDNISONE [Pred] 60 mg/m2 per day PO... D1-5
    Followed by tapering dose 40,20,10 mg/day

CYCLE: 14 days
REFER: Luce JK, et al: CANCER 1971; 28:306-317.




DISEASE: Lymphoma: Non Hodgkin's

REGIMEN: CVP-1

    CYCLOPHOSPHAMIDE [CTX] 400 mg/m2 per day PO... D1-5

    VINCRISTINE [VCR] 1.4 mg/m2 IV... D1
    Maximum dose is 2 mg

    PREDNISONE [Pred] 100 mg/m2 per day PO... D1-5

CYCLE: 21 days
REFER: Bagley CM, et al: ANN INTERN MED 1972; 76:227-234.




DISEASE: Lymphoma: Non Hodgkin's

REGIMEN: DHAP

    CISPLATIN [CDDP] 100 mg/m2 CIV over 24 hrs... D1

    CYTARABINE [ARA-C] 2 g/m2 IV over 3 hrs... D2
    After Cisplatin repeat dose 12 hrs later for total dose of 4 g/m2

    DEXAMETHASONE [DEX] 40 mg per day PO or IV... D1-4
    For 4 days

CYCLE: 3-4 weeks
REFER: Velasquez WS, et al: BLOOD 1988; 71:117-122.




DISEASE: Lymphoma: Non Hodgkin's

REGIMEN: ESAP

    METHYLPREDNISOLONE[SOL] 500 mg per day IV... D1-4

    ETOPOSIDE [VP-16] 40 mg/m2 per day IV... D1-4

    CYTARABINE [ARA-C] 2 g/m2 IV... D5
    Over 2 hr, after completion of Cisplatin

    CISPLATIN [CDDP] 25 mg/m2 per day x 4 CIV... D1-4
    (Total Dose 100 mg)

CYCLE: As tolerated
REFER: Velasquez W, et al: PROC ASCO 1989; 8:256.




DISEASE: Lymphoma: Non Hodgkin's

REGIMEN: MACOP-B

    METHOTREXATE [MTX] 400 mg/m2 IV... weeks 2,6,10

    LEUCOVORIN [Leu] 15 mg PO
    q 6 hr x 6 doses, starting 24hr after MTX

    DOXORUBICIN [DOX] 50 mg/m2 IV... weeks 1,3,5,7,9,11
    Caution: Monitor cumulative dose (cardiac toxicity)

    CYCLOPHOSPHAMIDE [CTX] 350 mg/m2 IV... weeks 1,3,5,7,9,11

    VINCRISTINE [VCR] 1.4 mg/m2 IV... weeks 2,4,6,8,10,12
    Max dose 2mg

    BLEOMYCIN [BLEO] 10 units/m2 IV... weeks 4,8,12
    Caution: Monitor cumulative dose (pulmonary toxicity)

    PREDNISONE [Pred] 75 mg per day PO
    Tapered over last 15 days

CYCLE: None
REFER: Connors JM, et al (eds). Update on Treatment for Diffuse Large Cell Lymphoma. Wiley & Sons 1986; 37-43.




DISEASE: Lymphoma: Non Hodgkin's

REGIMEN: MIV

    MITOXANTRONE [DHAD] 10 mg/m2 IV... D1
    Caution: Monitor cumulative dose (cardiac toxicity)

    IFOSFAMIDE [IFF] 1500 mg/m2 per day IV... D1-3
    With MESNA

    ETOPOSIDE [VP-16] 150 mg/m2 per day IV... D1-3

CYCLE: 21 days
REFER: Herbrecht R, et al: PROC ASCO 1991; 10:278.




DISEASE: Lymphoma: Non Hodgkin's

REGIMEN: m-BACOD

    METHOTREXATE [MTX] 200 mg/m2 IV... D8,15

    LEUCOVORIN [Leu] 10 mg/m2 PO... D9,16
    q6h x 8 doses starting 24h after MTX

    BLEOMYCIN [BLEO] 4 units/m2 IV... D1
    Caution: Monitor cumulative dose (pulmonary toxicity)

    DOXORUBICIN [DOX] 45 mg/m2 IV... D1
    Caution: Monitor cumulative dose (cardiac toxicity)

    CYCLOPHOSPHAMIDE [CTX] 600 mg/m2 IV... D1

    VINCRISTINE [VCR] 1 mg/m2 IV... D1
    Maximum dose is 2 mg

    DEXAMETHASONE [DEX] 6 mg/m2 per day PO... D1-5

CYCLE: 3 Wks.
REFER: Shipp MA, et al: ANN INTERN MED 1986; 104:757-765.




DISEASE: Lymphoma: Non Hodgkin's

REGIMEN: PROMACE-CYTABOM

    PREDNISONE [Pred] 60 mg/m2 per day PO... D1-14

    DOXORUBICIN [DOX] 25 mg/m2 IV... D1
    Caution: Monitor cumulative dose (cardiac toxicity)

    CYCLOPHOSPHAMIDE [CTX] 650 mg/m2 IV... D1

    ETOPOSIDE [VP-16] 120 mg/m2 IV... D1

    CYTARABINE [ARA-C] 300 mg/m2 IV... D8

    BLEOMYCIN [BLEO] 5 units/m2 IV... D8
    Caution: Monitor cumulative dose (pulmonary toxicity)

    VINCRISTINE [VCR] 1.4 mg/m2 IV... D8
    Maximum dose is 2 mg

    METHOTREXATE [MTX] 120 mg/m2 IV... D8

    LEUCOVORIN [Leu] 25 mg PO... D9
    q6h x 4 doses starting 24 hrs after MTX

CYCLE: 21 days, next cycle begins on D22
REFER: Fisher RI, et al: PROC ASCO 1984; 242. Abstract.




DISEASE: Lymphoma: Non Hodgkin's

REGIMEN: VACOP-B

    ETOPOSIDE [VP-16] 50 mg/m2 IV... D1
    And 100 mg/m2 per day PO D2,3 of week 3,7,11

    DOXORUBICIN [DOX] 50 mg/m2 IV... weeks 1,3,5,7,9,11
    Caution: Monitor cumulative dose (cardiac toxicity)

    CYCLOPHOSPHAMIDE [CTX] 350 mg/m2 IV... weeks 1,5,9

    VINCRISTINE [VCR] 1.2 mg/m2 IV... weeks 2,4,6,8,10,12
    No maximum vincristine dose

    PREDNISONE [Pred] 45 mg/m2 PO... q Dx1 week, then q OD x 11 wks

    BLEOMYCIN [BLEO] 10 units/m2 IV... weeks 2,4,6,8,10,12
    Caution: Monitor cumulative dose (pulmonary toxicity)

CYCLE: None
REFER: Connors JM, et al: PROC ASCO 1990; 9:254.




Glaxo Wellcome

Medicine OnLine and UltiTech have no liability for content or goods on the Internet except as set forth in the Terms and Conditions of service.

=Please read the Disclaimer of Warranties before using information contained in this section.

© Copyright 1995-2009 UltiTech, Inc. All Rights Reserved.


Top Of Page | Regimens Index | DoseCalc Index ]
About Medicine OnLine Medicine OnLine Home PageCancer LibrariesDoseCalc OnlineOncology News
Cancer ForumsMedline SearchCancer LinksGlossary